-
Mashup Score: 3
A new arm of a clinical trial will investigate (Z)-endoxifen plus Verzenio in patients with ER-positive, HER2-negative breast cancer.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 6
In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
In this feature, Targeted Oncology spoke to experts in breast cancer treatment on the trends in management of toxicity with the growing drug class of antibody-drug conjugates.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Radiation followed by mastectomy and immediate breast reconstruction “holds tremendous promise,” as one researcher explained.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 4
In this feature, Targeted Oncology spoke to experts in breast cancer treatment on the trends in management of toxicity with the growing drug class of antibody-drug conjugates.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Analyzing ADC Treatment Sequencing in Advanced Breast Cancer - 5 day(s) ago
In the first article of a 2-part series, Virginia G. Kaklamani, MD, discussed her approach to biomarker testing and treatment sequencing for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer - PubMed - 5 day(s) ago
We aimed to study the incidence and genomic spectrum of actionable alterations (AA) detected in serial cfDNA collections from patients with metastatic breast cancer (MBC). Patients with MBC who underwent plasma-based cfDNA testing (Guardant360®) between 2015 and 2021 at an academic instit …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Shruti Tiwari, MD, discusses treatment advances in HER2-positive and HER2-low breast cancer and looks ahead to the future of the space.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0FDA Receives Type C Meeting Request for Pelareorep in HR+/HER2– Metastatic Breast Cancer - 8 day(s) ago
The FDA has received a type C meeting request from Oncolytics Biotech to discuss a registration-enabling trial for pelareorep in HR+/HER2– breast cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Diagnosing HER2+ Breast Cancer - 9 day(s) ago
Rebecca A. Shatsky, MD, provides an overview of the current methods for diagnosing HER2+ breast cancer, highlighting immunohistochemistry and in situ hybridization.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
A new arm of the I-SPY 2 trial will evaluate (Z)-endoxifen plus Verzenio in patients with ER-positive, HER2-negative breast cancer. #BCSM https://t.co/LbCaiQamuI